The publisher’s final edited version anti-depressents have proven effective in reducing cravings. Second, a few of the of this article is available at Psychosom Med.
Yes, nortriptyline approximately doubles smoking cessation rates, an effect comparable to bupropion. Selective serotonin reuptake inhibitors SSRIs; fluoxetine, paroxetine, sertraline, citalopram, venlafaxine, monoamine oxidase inhibitors MAOIs; moclobemide, selegiline, doxepin, and St. Bupropion is the only Food and Drug Administration FDA -approved antidepressant recommended as a first-line pharmacologic agent to assist with smoking cessation, based in part on a meta-analysis of 44 placebo-controlled RCTs 13, patients, which found that bupropion had a relative risk RR of 1. A Cochrane systematic review of 10 antidepressants used for smoking cessation included 64 placebo-controlled trials, measuring at least 6-month abstinence rates as primary outcomes, and monitoring biochemical markers such as breath carbon monoxide and urinary cotinine to verify abstinence. Nortriptyline, which was evaluated in 6 trials, was the only antidepressant besides bupropion that was superior to placebo. One trial found no difference in quit rates for patients taking nortriptyline with or without a history of major depression, although the subgroups were small. Two trials measured quit rates for 12 months whereas the other 4 trials used 6-month quit rates. Coronavirus News Center.
See other articles in PMC that cite the published article. In both of these measures, the increase observed in response to smoking was similar for both treatments, however the further increase that occurred during the speech was smaller when taking paroxetine than when taking placebo table 2. Trial Registration : Tob Control. I started taking paxil because I quit smoking and felt that I needed some “help” to keep me smoke-free